XAIR Reports Q4 Earnings

On Friday, Beyond Air (NASDAQ: XAIR ) discussed fourth-quarter financial results during its earnings call. The full transcript is provided below. This content is powered APIs. 7 million for fiscal year 2026, driven by strong customer retention and new hospital adoption.

S. market fourfold. S. group purchasing organizations, enhancing its market access.

R&D and SG&A expenses decreased significantly by 39% and 27% respectively, reflecting cost structure improvements and prior restructuring activities. The company provided guidance for $8 million in revenue for calendar year 2026 and projected $16 to $18 million for 2027, indicating over 110% growth, assuming FDA approval and Gen 2 launch. The company successfully reduced its net cash burn by 56% year-over-year and addressed its Nasdaq listing compliance with a 1-for-20 reverse split. CEO Robert Goodman emphasized the importance of the Gen 2 LungFit system approval as a near-term catalyst and highlighted the company's disciplined capital allocation towards LungFit PH.

Full Transcript OPERATOR Good morning everyone and welcome to the Beyond Air financial results call for the fiscal year ended March 31, 2026. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. And now I'd like to turn the call over to Garth Russell with LifeSci Advisors.

Please go ahead. Garth Russell, LifeSci Advisors Thank you, Operator. Good morning everyone and thank you for joining us. Earlier today we issued a press release announcing the operational highlights and financial results for Beyond Air's fiscal year ended March 31, 2026.

A copy of this press release can be found on our website under the News and Events section. Before we begin, I would like to remind everyone that we will be making comments and various remarks about future expectations, plans, and prospects which constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Beyond Air cautions that these forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those indicated.

We encourage everyone to review the Company's filings with the Securities and Exchange Commission, including without limitation, the Company's most recent Form 10-K and Form 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Additionally, this conference call is being recorded and will be available for audio rebroadcast on our website, Furthermore, the content of this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, June 26, 2026.

Beyond Air undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this call. With that, I'll now turn the call over to Robert Goodman, Chief Executive Officer of Beyond Air. Bob, the floor is yours. Robert Goodman, Chief Executive Officer Thanks, Garth, and good morning to everyone.

Also here with me today is Dan Moorhead, our Chief Financial Officer. This is my first earnings call as Chief Executive Officer, and I'm excited to lead Beyond Air during what I believe is a pivotal moment for the Company. Over the last several months, I've spent a lot of time with our customers, commercial organization, distribution partners, and board, and those discussions have only strengthened my conviction that LungFit PH represents a significant commercial opportunity to establish Beyond Air as a leader in the nitric oxide market.

As a leadership team, we've become increasingly focused on aligning our commercial strategy, R&D efforts, and operating expenses across our core business, particularly as we move closer to regulatory approval of our second-generation LungFit system. This strategic focus is reflected in what we believe is an important inflection point for the business in the near term with our Gen 2 system. If approved, we expect to be more competitive and offer a more attractive solution for a broader range of hospital systems with external transport needs. As a result, we see the potential to immediately expand our total addressable market to over $1 billion globally.

Accordingly, our strategy is very straightforward. We are allocating our resources with discipline towards the opportunities we believe can create the greatest near and long-term value, including adoption of our current commercial LungFit system and preparing for the launch of our Gen 2 system. Fiscal 2026 displayed meaningful progress toward this goal. 7 million in the currently smaller addressable market driven by strong retention among our existing customer base and continued new hospital adoption.

Importantly, our customer renewal rate was approximately 90%, which reflects the value LungFit PH is delivering in clinical practice and the confidence our customers have in our technology and operational service support. This high level of customer satisfaction should be directly transposable to the Gen 2 device, and we continue to receive consistent feedback from our potential future customers that they're waiting for our next-generation platform to help meet all of their comprehensive INO req